Hidradenitis Suppurativa Market - 2022

October 2025 | 200 pages | ID: H390C8AB85C3EN
DataM Intelligence

Abstracts

The Hidradenitis Suppurativa Market was valued at USD 725.6 million in 2022 and is anticipated to reach by , at a CAGR of 0.048 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Hidradenitis Suppurativa Market.

This report delivers a comprehensive overview of the Hidradenitis Suppurativa Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Hidradenitis Suppurativa Market. The Hidradenitis Suppurativa Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2022–.

Hidradenitis Suppurativa Market Scope:

By Clinical Stage

• Hurley Stage 1
• Hurley Stage 2
• Hurley Stage 3

By Skin Condition

• Folliculitis
• Pimples
• Boils
• Deep-Acne
• Others

By Treatment Type

• Surgery
• Medications
• Photodynamic Therapy (PDT)
• Laser Treatment
• Others

By Route of Administration

• Oral
• Parenteral
• Others

By End-user

• Hospitals
• Specialty Clinics
• Homecare
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Key Players

• Pfizer Inc.
• Eli Lilly and Company
• AbbVie Inc.
• UCB S.A.
• Incyte Corporation
• Novartis AG
• Boehringer Ingelheim
• Aclaris Therapeutics, Inc.
• InflaRx N.V.
• Moonlake Immunotherapeutics

Major Highlights

This report delivers a comprehensive overview of the Hidradenitis Suppurativa Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Hidradenitis Suppurativa Market. The Hidradenitis Suppurativa Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2022–.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

• Increase Your Customer Base by 3X using our Partner Identification tool
• Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
• Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
• Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

3.1. Snippet by Clinical Stage
3.2. Snippet by Skin Condition
3.3. Snippet by Treatment Type
3.4. Snippet by Route of Administration
3.5. Snippet by Distribution Channel
3.6. Snippet by End-user
3.7. Snippet by Region

4. DYNAMICS

4.1. Impacting Factors
  4.1.1. Drivers
    4.1.1.1. Increasing Prevalence of hidradenitis suppurativa
  4.1.2. Restraints
    4.1.2.1. Side effects associated with the treatment
  4.1.3. Opportunity
    4.1.3.1. Increasing research and development activities
  4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis

6. COVID-19 ANALYSIS

6.1. Analysis of COVID-19
  6.1.1. Scenario Before COVID-19
  6.1.2. Scenario During COVID-19
  6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion

7. RUSSIA-UKRAINE WAR ANALYSIS

8. ARTIFICIAL INTELLIGENCE ANALYSIS

9. BY CLINICAL STAGE

9.1. Introduction
  9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical Stage
  9.1.2. Market Attractiveness Index, By Clinical Stage
9.2. Hurley Stage 1*
  9.2.1. Introduction
  9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Hurley Stage
9.4. Hurley Stage

10. BY SKIN CONDITION

10.1. Introduction
  10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Skin Condition
  10.1.2. Market Attractiveness Index, By Skin Condition
10.2. Folliculitis*
  10.2.1. Introduction
  10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Pimples
10.4. Boils
10.5. Deep-Acne
10.6. Others

11. BY TREATMENT TYPE

11.1. Introduction
  11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  11.1.2. Market Attractiveness Index, By Treatment Type
11.2. Surgery*
  11.2.1. Introduction
  11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Medications
  11.3.1. Biologics
  11.3.2. Antibiotics
  11.3.3. Hormonal Therapy
  11.3.4. Immunosuppressive Drugs
  11.3.5. Zinc Supplements
  11.3.6. Retinoids
  11.3.7. Pain Medication
11.4. Photodynamic Therapy (PDT)
11.5. Laser Treatment
11.6. Others

12. BY ROUTE OF ADMINISTRATION

12.1. Introduction
  12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  12.1.2. Market Attractiveness Index, By Route of Administration
12.2. Oral*
  12.2.1. Introduction
  12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Parenteral
12.4. Others

13. BY END-USER

13.1. Introduction
  13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  13.1.2. Market Attractiveness Index, By End-user
13.2. Hospitals*
  13.2.1. Introduction
  13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
13.3. Specialty Clinics
13.4. Homecare
13.5. Others

14. BY DISTRIBUTION CHANNEL

14.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14.2. Market Attractiveness Index, By Distribution Channel
14.3. Hospital Pharmacy*
  14.3.1. Introduction
  14.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
14.4. Retail Pharmacy
14.5. Online Pharmacy
14.6. Others

15. BY REGION

15.1. Introduction
  15.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  15.1.2. Market Attractiveness Index, By Region
15.2. North America
  15.2.1. Introduction
  15.2.2. Key Region-Specific Dynamics
  15.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical stage
  15.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Skin Condition
  15.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  15.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  15.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  15.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  15.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    15.2.9.1. The U.S.
    15.2.9.2. Canada
    15.2.9.3. Mexico
15.3. Europe
  15.3.1. Introduction
  15.3.2. Key Region-Specific Dynamics
  15.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical stage
  15.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Skin Condition
  15.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  15.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  15.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  15.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  15.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    15.3.9.1. Germany
    15.3.9.2. The U.K.
    15.3.9.3. France
    15.3.9.4. Italy
    15.3.9.5. Spain
    15.3.9.6. Rest of Europe
15.4. South America
  15.4.1. Introduction
  15.4.2. Key Region-Specific Dynamics
  15.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical stage
  15.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Skin Condition
  15.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  15.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  15.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  15.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  15.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    15.4.9.1. Brazil
    15.4.9.2. Argentina
    15.4.9.3. Rest of South America
15.5. Asia-Pacific
  15.5.1. Introduction
  15.5.2. Key Region-Specific Dynamics
  15.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical stage
  15.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Skin Condition
  15.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  15.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  15.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  15.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  15.5.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    15.5.9.1. China
    15.5.9.2. India
    15.5.9.3. Japan
    15.5.9.4. Australia
    15.5.9.5. Rest of Asia-Pacific
15.6. Middle East and Africa
  15.6.1. Introduction
  15.6.2. Key Region-Specific Dynamics
  15.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical stage
  15.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Skin Condition
  15.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  15.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  15.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  15.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

16. COMPETITIVE LANDSCAPE

16.1. Competitive Scenario
16.2. Product Benchmarking
16.3. Company Share Analysis
16.4. Key Developments and Strategies

17. COMPANY PROFILES

17.1. Pfizer Inc.*
  17.1.1. Company Overview
  17.1.2. Product Portfolio and Description
  17.1.3. Financial Overview
  17.1.4. Key Developments
17.2. Eli Lilly and Company
17.3. AbbVie Inc.
17.4. UCB S.A.
17.5. Incyte Corporation
17.6. Novartis AG
17.7. Boehringer Ingelheim
17.8. Aclaris Therapeutics, Inc.
17.9. InflaRx N.V.
17.10. Moonlake Immunotherapeutics (*LIST NOT EXHAUSTIVE)

18. APPENDIX

18.1. About Us and Services
18.2. Contact Us